Dr. Aaron Philip Mitchell, MD

Dr. Mitchell practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Mitchell's NPI, 1437423290, was assigned on February 26, 2012. Dr. Mitchell graduated from New York University School of Medicine in 2011. Dr. Mitchell's North Carolina license number on file is 2014-00595.

Dr. Mitchell's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Mitchell's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Mitchell to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mitchell practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Mitchell's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Mitchell is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Mitchell's licenses on file in 4 states: North Carolina, Florida, New Jersey and New York.

Dmand AI lists prostate cancer among the conditions Dr. Mitchell treats.

CMS data shows 407 Medicare services from Dr. Mitchell across 8 procedure codes in 2024, for 103 Medicare patients. Medicare paid $26,495 for them.

CMS counts 103 Medicare patients who saw Dr. Mitchell in 2024. The largest group is 65 to 74, with 42 patients. 75% of them have cancer, and 75% have high blood pressure. 18% are also on Medicaid. Their average risk score is 2.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mitchell's median patient age at 76, with 8% women.

In 2024, Dr. Mitchell wrote 301 Medicare Part D claims for 56 patients. 71% of them were for generic drugs. CMS names the drug for 194 of them, across 7 drugs with 11 or more claims each, at $1,118,130 in total drug cost. In 2023, CMS named 206 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 76 out of 100 for Dr. Mitchell for performance year 2024, reported as part of a group. Dr. Mitchell accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mitchell as offering telehealth.

Dmand AI links 197 papers to Dr. Mitchell, published from 2000 to 2025. 2020 was the busiest year, with 7. The most frequent topics are Candida albicans, Fungal Proteins and Saccharomyces cerevisiae. Dr. Mitchell has published most often in Mol Cell Biol. Dr. Mitchell's most frequent co-authors are Scott Filler, MD, Norma Solis, MD and Jeniel E. Nett, MD.

CMS Open Payments shows 1 general payment to Dr. Mitchell from 1 drug or device company in 2018. Grants make up the largest share, 100% of the total. Merck Sharp & Dohme Corporation paid the most, $1,000.

Dr. Mitchell graduated from New York University School of Medicine in 2011.

Dr. Mitchell is in network with 11 carriers, including Elevance, Aetna and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.